Interní Med. 2018; 20(4): 202-206 | DOI: 10.36290/int.2018.034

New European and Czech guidelines for hepatitis B therapy

prof. MUDr. Petr Husa, CSc.
Klinika infekčních chorob LF MU a FN Brno

Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors predominantlyvaccination policy and migration. Chronic hepatitis B means the duration of HBV infection for more than 6 months.It is a dynamic process reflecting the interaction between HBV replication and the host immune response and not all patientswith chronic HBV infection have chronic hepatitis B. All patients with chronic HBV infection are in increased risk of progression toliver cirrhosis and hepatocellular carcinoma. The long-term administration of potent nucleos(t)ide analogue with high barrier ofresistance (tenofovir, entecavir) represents the treatment of choice. Pegylated interferon-alpha can also be considered in mid tomoderate chronic hepatitis B patients.

Keywords: chronic hepatitis B, tenofovir, encetavir, pegylated interferon‑alpha

Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P. New European and Czech guidelines for hepatitis B therapy. Interní Med. 2018;20(4):202-206. doi: 10.36290/int.2018.034.
Download citation

References

  1. Husa P, Šperl J, Urbánek P, Fraňková S, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby infekce virem hepatitidy B. Gastroent Hepatol 2017; 71(5): 419-437. Go to original source...
  2. Husa P, Šperl J, Urbánek P, Fraňková S, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby infekce virem hepatitidy B. Datum vydání doporučení: září 2017. Klin mikrobiol inf lek 2017; 23(4): 148-164.
  3. Husa P, Šperl J, Urbánek P, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby chronické hepatitidy B. Gastroent Hepatol 2014; 68(6): 14-526. Go to original source...
  4. Husa P, Šperl J, Urbánek P, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby chronické hepatitidy B. Klin mikrobiol inf lek 2014; 20(4): 121-132.
  5. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017, http://dx.doi.org/10.1016/j.hep.2017.03.021.
  6. Němeček V, Částková J, Fritz P, et al. The 2001 serological survey in the Czech Republic-viral hepatitis. Cent Eur J Public Health 2003; 47(Suppl.1): S54-61.
  7. Bílková Fránková H, Kloudová A, Zelená H, et al. Víceúčelový sérologický přehled (spalničky, příušnice, pertusse, virová hepatitida B) SP 2013, ČR: Závěrečná zpráva. Zprávy CEM SZÚ 2014;23(Příloha 1):1-152.
  8. EPIDAT. Epidemiologická databáze Státního zdravotního ústavu Praha. Dostupné na: http://www.szu.cz/publikace/data/infekce-v-cr.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.